Monthly Archives: December 2017

Bitcoin’s Latest Sell-off Tests The Bottom Signaled By Google Tre...

At the time of writing, Bitcoin (BTC) just experienced another large one-day loss…currently around 10%. Source: Yahoo Finance  Selling resumed in Bitcoin (BTC) in the final hours of 2017, but the most recent low still holds. A week ago, sellers panicked and sent Bitcoin careening toward $10,000 as an orderly pullback from all-time highs suddenly became chaotic. Buyers…

Rule Of 20 Signals Stocks Are Expensive

Let’s review the bear market signposts individually to see if they imply a bear market is coming. 11 of the 19 warning signs have been triggered. In previous articles, I’ve reviewed the first 14 of them and determined that 4 are unreasonable, meaning less worry should be given about an oncoming bear market. The 15th signpost…

Best Of Old School Value 2017

Earlier in the year, we saw Britain exercise its decision to divorce the EU. They have until March 29, 2019 to come up with the terms and to have it signed and delivered. Maybe if things don’t go as planned, 2019 will finally be the year the market gets a cold. 2017 also marks the…

This Is Why Volatility Will Return In 2018

I In this crucial extended end of the year video we analyze why volatility will return in 2018. 2017 was the lowest volatility year on record. Risks in 2018 include interest rates increasing, central banks around the world reducing QE programs, and the FOMC selling off their balance sheet. Watch this video to find out…

E

The good news for the improving U.S. economy is that business investment started to revive in 2017. Indeed, there is little doubt that business confidence has been improving. The business community loves the tax cuts which will be implemented. But as well, the energy industry seems to have stabilized, which brings with it a renewed…

Week In Review: 2017 Was Record Investment Year For China Life Sc

Shanghai’s SARI will pay $359 million to acquire a 90% interest in Group NMS, a Milan oncology biopharma (see story). SARI is a biopharma investment firm affiliated with the Chinese Academy of Science research organization with the same name. SARI intends to bring NMS oncology drug candidates to China and integrate the features of the NMS development technology into its own. For the NMS…